Gilead says new data from four collaborative HIV studies reported at CROI

Gilead Sciences announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy, or ART, stating that these latest findings "represent an ongoing multi-pronged approach in Gilead’s HIV cure research program." The data were presented at the Conference on Retroviruses and Opportunistic Infections, or CROI, 2023 in Seattle. "The insights generated by the studies presented at CROI this year are advancing scientific knowledge on potential paths to a cure for HIV and expanding global understanding of what role broadly neutralizing antibodies, vaccines, and immune modulators may play in the future of HIV for people living with the virus. Gilead will continue exploring novel combination strategies in our pursuit to help end the HIV epidemic for everyone, everywhere," said Devi SenGupta, Executive Director, HIV Clinical Development, Gilead Sciences.